Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients

By Reuters News

- Regeneron Pharmaceuticals, Inc. REGN.O:

  • UBAMATAMAB (MUC16XCD3) SHOWS A HIGH RATE OF DURABLE RESPONSES IN INITIAL STUDY OF PATIENTS WITH ADVANCED LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)

  • REGENERON PHARMACEUTICALS, - UBAMATAMAB SHOWS 73% OBJECTIVE RESPONSE RATE AND 11-MONTH MEDIAN PFS IN LGSOC PATIENTS

  • REGENERON PHARMACEUTICALS, - 9-MONTH MEDIAN DURATION OF RESPONSE OBSERVED AT 800 MG UBAMATAMAB DOSE

  • REGENERON PHARMACEUTICALS, - TEAES OCCURRED IN 100% OF LGSOC PATIENTS; CYTOKINE RELEASE SYNDROME IN 90%, ALL GRADE 1 OR 2

  • REGENERON PHARMACEUTICALS, - SERIOUS TEAES GRADE 3+ IN 21% OF LGSOC PATIENTS; TRAES IN 74%; NEUTROPENIA, ANEMIA, ELEVATED LIVER ENZYMES

  • REGENERON PHARMACEUTICALS, - TO ADVANCE UBAMATAMAB INTO CONFIRMATORY PHASE 3 TRIAL FOR LGSOC

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk